The European Commission (EC) has approved cannabidiol (Epidyolex) oral solution as adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older.

DUBLIN--(BUSINESS WIRE)--The "Tuberous Sclerosis Complex - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Tuberous Sclerosis Complex Pipeline Insight, 2020 ...

Patients with tuberous sclerosis complex, a genetic disorder characterized by the growth of noncancerous tumors in multiple organs of the body, have limited treatment options. A team led by ...

Tuberous Sclerosis Complex (TSC) affects between one and two of every 10,000 new-born babies. This genetic disease leads to the formation of benign tumors which can massively impair the proper ...

Please provide your email address to receive an email when new articles are posted on . Survey responses reflected positive language and communication outcomes after cannabidiol use. Further ...

Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer ...

SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). This is an ...

The Tuberous Sclerosis Complex (TSC) Fellowship at UAB provides an opportunity for pediatric and adult neurologists with an interest in TSC clinical research and patient care to develop specialized ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...